- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01149161
Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Jee Soo Kim, M.D., Ph.D.
- Phone Number: 82-2-3410-3479
- Email: js0507.kim@samsung.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Recruiting
- Samsung Medical Center
-
Contact:
- Jee Soo Kim, M.D., Ph.D.
- Phone Number: 82-2-3410-3479
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- papillary carcinoma of thyroid (less than 4cm)
- no evidence of lymph node metastasis in preoperative work-up result
- the patients who accept this study
Exclusion Criteria:
- large thyroid cancer( > 4cm)
- morbid
- anticoagulation agent usage
- endoscopic or robotic thyroid operation
- evidence of lymph node metastasis or extrathyroidal extension in preoperative US and CT scan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: C group
Routine central neck dissection
|
Level VI neck node dissection during thyroid operation
|
No Intervention: N group
No central neck node dissection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Is routine neck node dissection necessary in micro PTC?
Time Frame: Until 5 year follow-up. (Dec. 2016)
|
To see the necessity of routine neck node dissection in micro PTC, we will compare the recurrence rate and other complication (e.g. hoarseness and hypocalcemia) between group I(no dissection) and group III(routine dissection) after completion of study(after 5 year f/u). To check the safety of this study, our result will be checked by korea institutional reveiw board every one year. |
Until 5 year follow-up. (Dec. 2016)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The efficacy of sentinel lymph node biopsy in micro PTC
Time Frame: Until 5 year follow-up. (Dec. 2016)
|
Until 5 year follow-up. (Dec. 2016)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jee Soo Kim, M.D., Ph.D., Samsung Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-02-017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingCancer Survivor | Invasive Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
Clinical Trials on Routine central neck dissection
-
Assiut UniversityUnknownPapillary Thyroid CancerEgypt
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Guang-Yan YuNational Natural Science Foundation of China; Peking University School of StomatologyRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedPatients With Papillary Thyroid Cancer and N1b StatusItaly
-
Shanghai Ninth People's Hospital Affiliated to...Not yet recruitingOral Squamous Cell Carcinoma | Neck Dissection
-
Cancer Institute and Hospital, Chinese Academy...Jilin Provincial Tumor Hospital; Hebei Medical University Fourth Hospital; Liaoning... and other collaboratorsUnknownLaryngeal Neoplasms | Malignant Neoplasm of Supraglottis Primary | Neck DislocationChina
-
Centro de Excelencia en Enfermedades de Cabeza...Hospital San Vicente Fundación; Hospital Alma Mater de Antioquia; Clinica Las...Recruiting
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital...UnknownOral Squamous Cell CarcinomaChina
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting